Table 2. Univariate analysis of prognostic factors in 112 patients.
| Factors | Median PFS (months) | P | Median OS (months) | P |
|---|---|---|---|---|
| Sex | 0.858 | 0.024 | ||
| Male | 10.2 | 22.1 | ||
| Female | 9.8 | NA | ||
| Age (years) | 0.625 | 0.207 | ||
| <65 | 10.2 | 31.3 | ||
| ≥65 | 9.8 | 18.6 | ||
| Smoking status | 0.755 | 0.234 | ||
| Ever smoker | 9.8 | 21.4 | ||
| Never smoker | 10.2 | 29.8 | ||
| ECOG score | NA | NA | ||
| 0–1 | 9.8 | 29.8 | ||
| 2 | NA | NA | ||
| Disease stage | 0.622 | 0.641 | ||
| IIIB | 8.2 | 18.0 | ||
| IV | 9.8 | 29.8 | ||
| EGFR mutation status | 0.991 | 0.056 | ||
| Wild type | 10.2 | 21.4 | ||
| Positive mutation | 9.3 | 29.8 | ||
| ALK status | 0.253 | 0.937 | ||
| Negative | 10.2 | 29.8 | ||
| Positive | 7.4 | 40.1 | ||
| Brain metastases | 0.069 | 0.009 | ||
| Present | 6.9 | 23.8 | ||
| Absent | 10.2 | 40.1 | ||
| Thoracic radiotherapy | 0.962 | 0.493 | ||
| Yes | 10.2 | 29.8 | ||
| No | 9.8 | 24.8 | ||
| Maintenance therapy | <0.001 | 0.001 | ||
| Yes | 11.5 | 40.1 | ||
| No | 6.8 | 18.0 | ||
PFS, progression-free survival; OS, overall survival; ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; NA, not available.